GPER Mediates Cardiotropic Effects in Spontaneously Hypertensive Rat Hearts

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  de Francesco, Ernestina Marianna ^a   Angelone, Tommaso ^a   Pasqua, Teresa ^a   Pupo, Marco ^a   Cerra, Maria Carmela ^a   Maggiolini, Marcello ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; G PROTEIN COUPLED RECEPTOR 30; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN C JUN; PROTEIN GSK3BETA; PROTEIN KINASE B; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; HEART PERFUSION; HEART PROTECTION; INOTROPISM; ISOLATED HEART; LUSITROPISM; MALE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; TISSUE DISTRIBUTION;

EID: 84881244793     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069322     Document Type: Article

References (68)

1. Vitale C, Fini M, Speziale G, Chierchia S, (2010) Gender differences in the cardiovascular effects of sex hormones. Fundam Clin Pharmacol 24: 675-685.
2. Murphy E, (2011) Estrogen signaling and cardiovascular disease. Circ Res 109: 687-696.
3. Mendelsohn ME, (2002) Protective effects of estrogen on the cardiovascular system. Am J Cardiol 89: 12E-17E.
4. Mendelsohn ME, Karas RH, (1999) Mechanisms of disease: the protective effects of estrogen on the cardiovascular system. New Engl. J Med 340: 1801-1811.
5. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA, (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad 93: 5925-5930.
6. Panno ML, Salerno M, Pezzi V, Sisci D, Maggiolini M, et al. (1996) Effect of oestradiol and insulin on the proliferative pattern and on oestrogen and progesterone receptor contents in MCF-7 cells. J Cancer Res Clin Oncol 122: 745-749.
7. Pedram A, Razandi M, Levin ER, (2006) Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 20: 1996-2009.
8. Meyer MR, Haas E, Prossnitz ER, Barton M, (2009) Non-genomic regulation of vascular cell function and growth by estrogen. Mol Cell Endocrinol 308: 9-16.
9. Wyckoff MH, Chambliss KL, Mineo D, Yuhanna IS, Mendelsohn ME, et al. (2001) Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Galpha(i). J Biol Chem 276: 27071-27076.
10. Prossnitz ER, Maggiolini M, (2009) Mechanisms of estrogen signaling and gene expression via GPR30. Molecular and Cellular Endocrinology 308: 32-38.
11. Prossnitz ER, Barton M, (2011) The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 7: 715-726.
12. Maggiolini M, Picard D, (2010) The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 204: 105-114.
13. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, et al. (2004) The G Protein-coupled Receptor GPR30 Mediates c-fos up-regulation by 17β-Estradiol and Phytoestrogens in Breast Cancer Cells. J Biol Chem 279: 27008-27016.
14. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, et al. (2006) 17beta-estradiol, genistein, and 4 hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein coupled-receptor GPR30. Mol Pharmacol 70: 1414-1423.
15. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, et al. (2006) The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20: 631-646.
16. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, et al. (2007) G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 67: 1859-1866.
17. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, et al. (2009) Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 28: 523-532.
18. Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, et al. (2010) Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol Cell Endocrinol 320: 162-170.
19. Chimento A, Sirianni R, Delalande C, Silandre D, Bois C, et al. (2010) 17 beta-estradiol activates rapid signaling pathways involved in rat pachytene spermatocytes apoptosis through GPR30 and ER alpha. Mol Cell Endocrinol 320: 136-144.
20. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr, (2000) Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14: 1649-1660.
21. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER, (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307: 1625-1630.
22. Thomas P, Pang Y, Filardo EJ, Dong J, (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146: 624-632.
23. Morley P, Whitfield JF, Vanderhyden BC, Tsang BK, Schwartz JL, (1992) A new nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinology 131: 1305-1312.
24. Meyer MR, Prossnitz ER, Barton M, (2011) The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. Vascul Pharmacol 55: 17-25.
25. Filice E, Recchia AG, Pellegrino D, Angelone T, Maggiolini M, et al. (2009) A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat. J Physiol Pharmacol 60: 3-10.
26. Deschamps AM, Murphy E, (2009) Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol 297: H1806-H1813.
27. Haas E, Bhattacharya I, Brailoiu E, Damjanovic M, Brailoiu GC, et al. (2009) Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res 104: 288-291.
28. Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC, (2009) Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology 150: 3753-3758.
29. Recchia AG, De Francesco EM, Vivacqua A, Sisci D, Panno ML, (2011) The G protein- coupled receptor 30 is upregulated by hypoxia-inducible factor-1alpha (HIF-1alpha) in breast cancer cells and cardiomyocytes. J Biol Chem 286: 10773-10782.
30. Angelone T, Filice E, Quintieri AM, Imbrogno S, Amodio N, et al. (2012) Receptor identification and physiological characterization of glucagon-like peptide-2 in the rat heart. Nutr Metab Cardiovasc Dis 22: 486-494.
31. Filice E, Angelone T, De Francesco EM, Pellegrino D, Maggiolini M, et al. (2011) Crucial role of phospholamban phosphorylation and S-nitrosylation in the negative lusitropism induced by17β-estradiol in the male rat heart. Cell Physiol Biochem 28: 41-52.
32. Angelone T, Quintieri AM, Pasqua T, Gentile S, Tota B, et al. (2012) Phosphodiesterase type-2 and NO-dependent S-nitrosylation mediate the cardioinhibition of the antihypertensive catestatin. Am J Physiol Heart Circ Physiol 302: H431-H442.
33. Maggiolini M, Donzé O, Picard D, (1999) A non-radioactive method for inexpensive quantitative RT-PCR. Biol Chem 380: 695-697.
34. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, et al. (2009) In vivo effects of a GPR30 antagonist. Nat Chem Biol 5: 421-427.
35. Lappano R, Recchia AG, De Francesco EM, Angelone T, Cerra MC, et al. (2011) The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor α-mediated signaling in cancer cells and in cardiomyocytes. PLoS ONE 6: e16631 doi: 10.1371/journal.pone.0016631.
36. Madeo A, Maggiolini M, (2010) Nuclear alternate estrogen receptor GPR30 mediates 17β-Estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res 70: 6036-6046.
37. Vivacqua A, Romeo E, De Marco P, De Francesco EM, Abonante S, et al. (2012) GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells. Breast Cancer Res Treat 133: 1025-1035.
38. Pupo M, Pisano A, Lappano R, Santolla MF, De Francesco EM, et al. (2012) Bisphenol A Induces Gene Expression Changes and Proliferative Effects through GPER in Breast Cancer Cells and Cancer-Associated Fibroblasts. Environ Health Perspec 120: 1177-1182.
39. Lappano R, Rosano C, Santolla MF, Pupo M, De Francesco EM, et al. (2012) Two Novel GPER Agonists Induce Gene Expression Changes and Growth Effects in Cancer Cells. Curr Cancer Drug Targets 12: 531-542.
40. Barton M, (2012) Position paper: The membrane estrogen receptor GPER-Clues and questions. Steroids 77: 935-942.
41. Patel VH, Chen J, Ramanjaneya M, Karteris E, Zachariades E, et al. (2010) G-protein coupled estrogen receptor 1 expression in rat and human heart: Protective role during ischaemic stress. Int J Mol Med 26: 193-199.
42. Delbeck M, Golz S, Vonk R, Janssen W, Hucho T, et al. (2011) Impaired left-ventricular cardiac function in male GPR30-deficient mice. Mol Med Repor 4: 37-40.
43. Jessup JA, Lindsey SH, Wang H, Chappell MC, Groban L, (2010) Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the GPER agonist G-1 in female mRen2.Lewis rats. PLoS ONE 5: e15433 doi: 10.1371/journal.pone.0015433.
44. Doggrell SA, Brown L, (1998) Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 39: 89-105.
45. Mitchell GF, Pfeffer JM, Pfeffer MA, (1997) The transition to failure in the spontaneously hypertensive rat. Am J Hypertens 10: 120S-126S.
46. Wang H, Jessup JA, Lin MS, Chagas C, Lindsey SH, et al. (2012) Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats. Cardiovasc Res 94: 96-104.
47. Park JH, Park M, Byun CJ, Jo I, (2012) c-Jun N-terminal kinase 2 phosphorylates endothelial nitric oxide synthase at serine 116 and regulates nitric oxide production. Biochem Biophys Res Commun 417: 340-345.
48. Bertrand J, Despeaux M, Joly S, Bourogaa E, Gallay N, et al. (2012) Sex differences in the GSK3β-mediated survival of adherent leukemic progenitors. Oncogene 31: 694-705.
49. Katoh M, Katoh M, (2006) Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol Ther 5: 1059-1064.
50. Hausenloy DJ, Yellon DM, (2007) Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 12: 217-234.
51. Schulman D, Latchman DS, Yellon D, (2002) Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol 283: H1481-H1488.
52. Penna C, Mancardi D, Raimondo S, Geuna S, Pagliaro P, (2008) The paradigm of postconditioning to protect the heart. J Cell Mol Med 12: 435-458.
53. Semenza GL, (2001) HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13: 167-171.
54. Semenza GL, Shimoda LA, Prabhakar NR, (2006) Regulation of gene expression by HIF-1. Novartis Found Symp 272: 2-8; discussion 8-14, 33-36.
55. Kuwahara F, Kai H, Tokuda K, Shibata R, Kusaba K, et al. (2002) Hypoxia-inducible factor-1alpha/vascular endothelial growth factor pathway for adventitial vasa vasorum formation in hypertensive rat aorta. Hypertension 39: 46-50.
56. Czibik G, (2010) Complex role of the HIF system in cardiovascular biology. J Mol Med (Berl) 88: 1101-1111.
57. Semenza GL, Prabhakar NR, (2007) HIF-1-dependent respiratory, cardiovascular, and redox responses to chronic intermittent hypoxia. Antioxid Redox Signal 9: 1391-1396.
58. Krick S, Eul BG, Hanze J, Savai R, Grimminger F, et al. (2005) Role of hypoxia inducible factor-1alpha in hypoxia-induced apoptosis of primary alveolar epithelial type II cells. Am J Respir Cell Mol Biol 32: 395-403.
59. Greijer AE, van der Wall E, (2004) The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57: 1009-1014.
60. Lei L, Mason S, Liu D, Huang Y, Marks C, et al. (2008) Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Mol Cell Biol 28: 3790-3803.
61. Sogawa K, Numayama-Tsuruta K, Ema M, Abe M, Abe H, et al. (1998) Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia. Proc Natl Acad Sci USA 95: 7368-7373.
62. Huang LE, Willmore WG, Gu J, Goldberg MA, Bunn HF, (1999) Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J Biol Chem 274: 9038-9044.
63. Adhikary G, Premkumar DR, Prabhakar NR, (2000) Dual influence of nitric oxide on gene regulation during hypoxia. Adv Exp Med Biol 475: 285-292.
64. Ao Q, Huang L, Zhu P, Xiong M, Wang D, (2004) Inhibition of expression of hypoxia-inducible factor-1alpha mRNA by nitric oxide in hypoxic pulmonary hypertension rats. J Huazhong Univ Sci Technolog Med Sci 24: 5-8.
65. Weil BR, Manukyan MC, Herrmann JL, Wang Y, Abarbanell AM, et al. (2010) Signaling via GPR30 protects the myocardium from ischemia/reperfusion injury. Surgery 148: 436-443.
66. Denger S, Reid G, Kos M, Flouriot G, Parsch D, et al. (2001) ERalpha gene expression in human primary osteoblasts: evidence for the expression of two receptor proteins. Mol Endocrinol 15: 2064-2077.
67. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, et al. (2005) Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 336: 1023-7.
68. Kang L, Zhang X, Xie Y, Tu Y, Wang D, et al. (2010) Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 24: 709-21.